IBEX Announces Stock Options Grant to Directors and Employees

IBEX Technologies Inc. (TSX VENTURE:IBT), today announces that the Company's
board of Directors has granted stock options representing a total of 300,000
common shares to its non-executive directors, and certain officers and employees
at an exercise price of $0.10


The options expire on March 26, 2018.

All of the stock options were granted under the IBEX stock option plan.

About IBEX

The Company markets a series of proprietary enzymes (heparinases and
chondroitinases) for research use, as well Heparinase I, which is used in many
leading hemostasis monitoring devices.


IBEX also markets a series of arthritis assays which are widely used in
pharmaceutical research. These assays are based on the discovery of a number of
specific molecular biomarkers associated with collagen synthesis and
degradation.


For more information, please visit the Company's web site at www.ibex.ca.

Safe Harbor Statement

All of the statements contained in this news release, other than statements of
fact that are independently verifiable at the date hereof, are forward-looking
statements. Such statements, based as they are on the current expectations of
management, inherently involve numerous risks and uncertainties, known and
unknown. Some examples of known risks are: the impact of general economic
conditions, general conditions in the pharmaceutical industry, changes in the
regulatory environment in the jurisdictions in which IBEX does business, stock
market volatility, fluctuations in costs, and changes to the competitive
environment due to consolidation or otherwise. Consequently, actual future
results may differ materially from the anticipated results expressed in the
forward-looking statements. IBEX disclaims any intention or obligation to update
these statements.